Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy - PubMed
3 hours ago
- #KEAP1/NRF2 Signaling
- #Small Cell Lung Cancer
- #Redox-targeting Therapy
- SCLC cells, like their origin cells, have low ROS defense pathways.
- TXNRD1 inhibitors rapidly deplete ROS-scavenging capacity in SCLC cells across subtypes and resistance status.
- SCLC cells cannot adapt to drug-induced ROS stress due to suppressed defense mechanisms.
- Pharmacological NRF2 activation increases therapeutic dose of TXNRD1 inhibitors safely in vivo.
- This approach improves tumor control without added toxicity to healthy tissues.